Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5282 - Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC) – initial report of a phase I study, MK3475-223

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Clinical Research;  Immunotherapy

Tumour Site

Presenters

Alon Ben Nun

Citation

Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290

Authors

A. Ben Nun1, N. Golan1, E. Ofek2, D. Urban3, I. Kamer3, D. Simansky1, A. Onn4, A. Ackerstein3, S.P. Raskin3, T. Shulimzon4, N. Zeitlin1, I. Redinsky3, S. Halperin3, M. Jurkowicz3, J. Bar3

Author affiliations

  • 1 Department Of Thoracic Surgery, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 2 Department Of Pathology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 3 Institute Of Oncology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
  • 4 Institute Of Pulmonology, Chaim Sheba Medical Center, 52621 - Ramat Gan/IL
More

Resources

Abstract 5282

Background

NSCLC is the most common cause of cancer-related death. Even clinical stage I or II tumors that are completely resected harbor a 5-year survival of only 30-50%. Immunotherapy is being investigated now as adjuvant therapy and might improve those results. We hypothesize that neo-adjuvant immunotherapy is a feasible, safe and effective treatment for early stage NSCLC.

Methods

MK3475-223 is a phase I study, testing neoadjuvant Pembro for stage I and II NSCLC. Study design is based on a classical 3 + 3 cohort, but the differences between cohorts are not drug dose but number of treatments (1st cohort 1 treatment, 2nd and 3rd cohorts 2 treatments with a 3 weeks (wk) interval between them) prior to surgery, and interval from last dose to surgery (1st cohort 3 wks, 2nd cohort 2 wks, 3rd cohort 1 wk). All Pembro treatments are 200mg. Primary objectives are to determine safety, recommended phase 2 dose/schedule, pathological and radiological response. Dose limiting toxicities (DLT) were defined as significant surgical complications (bleeding, delayed wound healing, acute respiratory distress syndrome, prolonged air-leak) or a significant delay of surgery. DLT period was defined as 30 days post-surgery.

Results

To date, two cohorts (6 patients (pts)) have been fully recruited and completed the DLT period. No DLT has occurred. Adverse events (AEs) are within the recognized AE profile of Pembro and of thoracic surgical procedures. No significant responses were seen in the 1st cohort (1 Pembro treatment, 3 wks later surgery). Out of 3 pts on the 2nd cohort (2 Pembro treatments, 2 wks later surgery), 2 pts (66.6%) demonstrate near complete pathologic response, with less than 1% of tumor cells left estimated. The study is ongoing and continuing to recruit, currently recruiting the final cohort (2 pembro treatments, 1 wk later surgery), to be followed by an expansion cohort.

Conclusions

Neoadjuvant Pembro is a promising option for early stage NSCLC. Initial data suggest the safety of this approach. The trial will provide initial evidence as well as correlative studies regarding the efficacy of this approach.

Clinical trial identification

Legal entity responsible for the study

Sheba Medical Center.

Funding

MSD.

Editorial Acknowledgement

Disclosure

J. Bar: Consultant fees: Roche, Boehringer Ingelheim, Novartis, BMS, MSD, Pfizer, AstraZeneca, Takada, Abbvie, VBL; Grant support: Boehringer Ingelheim, AstraZeneca, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.